Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Notes Payables (2025)

Historic Notes Payables for Ernexa Therapeutics (ERNA) over the last 3 years, with Q1 2025 value amounting to $2.2 million.

  • Ernexa Therapeutics' Notes Payables changed N/A to $2.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $631000.0 for FY2013, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, Ernexa Therapeutics' Notes Payables is $2.2 million.
  • Over the past 5 years, Ernexa Therapeutics' Notes Payables peaked at $2.2 million during Q1 2025, and registered a low of $2.2 million during Q1 2025.